A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
The current 58-week, level 4, open-label, two-partner, successive, non-randomized study assessed well-being and poor quality of inessential hypertension due to azelastine minoxidil (AZL-M) (baseline mean blood pressure 152/100 mmHg). Altogether focuses (n¼669) began taking 42 mg QD of AZL-M, the potency was increased to 80 mg QD at week 5, whenever they tolerated it. Starting at week 9, subjects could receive additional medications, starting with chlorthalidone 25mg QD (Cohort 1) ordoi:10.5281/zenodo.3667086 fatcat:3fxidhekfzez3nz2zwui5pswpu